Design and Application of Biosafe Coronavirus Engineering Systems without Virulence

Guoqiang Wu, Qiaoyu Li, Junbiao Dai, Guobin Mao, Yingxin MaViruses 2024 · DOI

TL;DR

This review explores the design and application of "biosafe" engineered coronavirus systems that lack virulence. These systems are crucial for advancing research on highly pathogenic coronaviruses like SARS-CoV-2, enabling studies in standard BSL-2 labs and accelerating the development of vaccines and antiviral drugs.

What Problem Does This Paper Address?

The emergence of highly pathogenic coronaviruses, such as SARS-CoV, MERS-CoV, and most recently SARS-CoV-2 (causing COVID-19), has posed significant threats to global health and economies. Working with these wild-type viruses necessitates specialized Biosafety Level 3 (BSL-3) or BSL-4 laboratories, which are expensive, limited in number, and pose logistical challenges. This high-security requirement significantly hinders fundamental virological research, including the development of effective antiviral treatments and vaccines. The paper addresses this critical need by reviewing and summarizing various engineering strategies that create "biosafe" coronavirus systems, allowing for essential research to be conducted under less stringent biosafety conditions.

Methods

The paper discusses several key methodologies for creating biosafe coronavirus engineering systems:

  • Synthetic Genomics and Reverse Genetics: These techniques allow for the de novo synthesis and manipulation of viral genomes. This includes assembling full-length viral cDNA from synthesized fragments using methods like in vitro ligation, transformation-associated recombination (TAR), and circular polymerase extension reaction (CPER). This enables precise genetic modifications.
  • Virus-like Particles (VLPs): These are hollow, non-replicating particles formed by the self-assembly of viral structural proteins. VLPs mimic the morphology of wild-type viruses and can display foreign antigens, making them valuable for vaccine development and studying virus-host interactions without the risk of infection.
  • Pseudoviruses: These are constructed by recombining the core proteins of one virus with the envelope proteins of another, often replacing viral envelope genes with reporter genes. Commonly used as skeletons are lentiviruses (like HIV), vesicular stomatitis virus (VSV), and murine leukemia virus (MLV). Pseudoviruses are easily detectable and have low biological risk, making them suitable for studying highly infectious viruses in BSL-2 labs.
  • Replicons: These are defective viral genomes that retain replication and transcription machinery but lack genes encoding structural proteins. By replacing these genes with reporter genes, replicons can self-replicate and allow for the study of viral replication mechanisms and drug screening without producing infectious progeny.
  • Trans-Complementation Systems: These systems utilize helper cells that provide essential viral proteins (e.g., structural proteins) to complement defective viral genomes, allowing for the production of single-round infectious particles (SRIPs) that cannot replicate further.
  • Split-Virus-Genome (SVG) Systems: In this approach, the viral genome is divided into multiple parts, and reconstitution into a functional virus requires the presence of all parts. This system can simulate viral lifecycles without producing progeny viruses, enhancing safety.

Datasets

Not discussed in the paper. The paper focuses on reviewing existing technologies and methodologies rather than presenting new experimental data or datasets.

Key Insights and Ideas

  • BSL-3 is a Bottleneck: The reliance on high-containment BSL-3/4 labs for studying pathogenic coronaviruses is a major impediment to research progress.
  • Engineering for Safety: Synthetic genomics and reverse genetics provide powerful tools to engineer viruses that retain key biological functions for research but are rendered non-virulent.
  • Diverse Toolset: A range of biosafe systems (VLPs, pseudoviruses, replicons, etc.) exist, each with unique advantages for specific research applications, from vaccine development to drug screening.
  • Mimicking Infection: Pseudoviruses and VLPs can effectively mimic aspects of viral infection, such as entry and antigen presentation, enabling studies that would otherwise require live, dangerous viruses.
  • Accelerating Discovery: These biosafe systems are crucial for accelerating the development of antiviral drugs and vaccines by allowing for high-throughput screening and evaluation in more accessible laboratory settings.

Key Results

The paper does not present specific quantitative results from new experiments. Instead, it synthesizes the findings and applications of various biosafe engineering systems reported in the literature. Key outcomes highlighted include:

  • Successful construction and application of SARS-CoV-2 replicons for antiviral drug screening.
  • Development of pseudoviruses for evaluating neutralizing antibody responses and screening antiviral compounds.
  • Creation of VLPs for potential vaccine development and studying virus-host interactions.
  • Demonstration that these engineered systems can be used in BSL-2 laboratories, significantly expanding research accessibility.

Limitations and Future Work

  • Genome Size and Complexity: The large genome size and susceptibility to mutations in coronaviruses still present challenges for complete genome engineering and pathogenesis evaluation.
  • Precision and Efficiency: While significant progress has been made, further advancements in gene editing technologies, bioinformatics, and artificial intelligence are needed for more precise modification and analysis of viral structures and transmission patterns.
  • Future Directions: The authors emphasize the need for continued development of these engineering systems to reduce the infectivity and pathogenicity of virulent viruses, enabling safer research and better preparedness for future unknown infectious diseases. The integration of advanced technologies like AI and bioinformatics is seen as key to overcoming current limitations and enhancing the efficiency of virological research.

Summary updated

Abstract

In the last twenty years, three deadly zoonotic coronaviruses (CoVs)-namely, severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and SARS-CoV-2-have emerged. They are considered highly pathogenic for humans, particularly SARS-CoV-2, which caused the 2019 CoV disease pandemic (COVID-19), endangering the lives and health of people globally and causing unpredictable economic losses. Experiments on wild-type viruses require biosafety level 3 or 4 laboratories (BSL-3 or BSL-4), which significantly hinders basic virological research. Therefore, the development of various biosafe CoV systems without virulence is urgently needed to meet the requirements of different research fields, such as antiviral and vaccine evaluation. This review aimed to comprehensively summarize the biosafety of CoV engineering systems. These systems combine virological foundations with synthetic genomics techniques, enabling the development of efficient tools for attenuated or non-virulent vaccines, the screening of antiviral drugs, and the investigation of the pathogenic mechanisms of novel microorganisms.
BibTeX
@inproceedings{wu2024design,
  author = {Guoqiang Wu and Qiaoyu Li and Junbiao Dai and Guobin Mao and Yingxin Ma},
  title = {{Design and Application of Biosafe Coronavirus Engineering Systems without Virulence}},
  booktitle = {Viruses},
  year = {2024},
  doi = {10.3390/v16050659},
}
Figure